Beyond the Shopping List: Is Your Asset Ready for Financing or BD?
Translating broad buyer interest into disease, patient, evidence-package, and development-path requirements — and knowing whether your asset actually meets them.
The second episode of NAPPA Healthcare & Biopharma Insights turns from policy to deal-making. Buyers and investors rarely lack interest — what they lack is conviction that an asset fits their disease priorities, patient populations, evidence expectations, and development timelines. This session is about closing that gap before you walk into the room.
Dr. Joy Wang (PhD, MBA), NAPPA Strategic Advisor, draws on more than twenty years of senior portfolio-strategy leadership at Novartis/Sandoz, Eli Lilly, Baxter, and Dendreon — spanning neuroscience, oncology, and cell & gene therapy — to lay out the decision frameworks acquirers and financiers actually use, and how to pressure-test an asset against them.
The session is open to NAPPA members, partners, and qualified industry guests. Seats are limited — register below to receive Zoom join details.
Key topics.
- ✓ Translating broad buyer interest into concrete asset requirements
- ✓ Matching disease, patient population, and development path
- ✓ Building the evidence package financing and BD partners expect
- ✓ Evaluating an asset's true competitive advantage
- ✓ Key criteria for financing vs. BD opportunities
- ✓ Real-world cross-border deal-making and case studies
Gain a global perspective on evaluating an asset's true competitive advantage.
Identify the key criteria that determine financing or BD opportunities.
Match disease, patient, evidence, and development path for a successful deal.
Learn from real-world cross-border deal-making and case studies.
Reserve your seat.
Registration is free for NAPPA members and qualified industry guests. Join details will be sent to your email immediately after registering.